Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

SHA:600211 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	2,808	2,800	3,128	2,545	2,127	1,362
Other Revenue	6.73	6.73	6.24	9.69	12.06	11.49
Revenue	2,815	2,807	3,134	2,555	2,139	1,373
Revenue Growth (YoY)	-3.99%	-10.45%	22.69%	19.45%	55.75%	9.32%
Cost of Revenue	163.05	162.1	158.67	204.74	225.8	195.69
Gross Profit	2,652	2,645	2,976	2,350	1,913	1,177
Selling, General & Admin	1,677	1,685	1,881	1,541	1,254	747.78
Research & Development	31.29	28.94	17.35	88.13	60.86	7.46
Other Operating Expenses	112.97	37.1	38.17	32.54	26.2	14.47
Operating Expenses	1,822	1,751	1,937	1,662	1,340	770.09
Operating Income	830.05	893.44	1,039	688.27	572.75	407.32
Interest Expense	-9.48	-9.48	-11.59	-14.36	-4.33	-1.05
Interest & Investment Income	77.39	74.38	86.22	21.35	2.67	11.43
Currency Exchange Gain (Loss)	-2.47	-2.47	-0.11	-3.83	-4.78	3.29
Other Non Operating Income (Expenses)	13.87	-0.17	-0.47	-0.39	-0.35	-0.26
EBT Excluding Unusual Items	909.36	955.69	1,113	691.03	565.96	420.73
Gain (Loss) on Sale of Investments	-18.28	-18.99	-210.53	-14.17	146.47	0.95
Gain (Loss) on Sale of Assets	1.73	1.9	0.34	-0.23	-0.17	-0.03
Asset Writedown	-	-	-190.38	-218.62	-458.06	-
Other Unusual Items	213.48	213.48	186.03	5.36	0.64	48.66
Pretax Income	1,106	1,152	898.19	463.39	254.85	470.32
Income Tax Expense	94.21	95.01	87.95	88.08	41.82	49.65
Earnings From Continuing Operations	1,012	1,057	810.24	375.31	213.03	420.66
Minority Interest in Earnings	-4.43	-5.79	-9.33	-5.47	-4.09	-2.57
Net Income	1,008	1,051	800.91	369.84	208.94	418.1
Net Income to Common	1,008	1,051	800.91	369.84	208.94	418.1
Net Income Growth	24.30%	31.26%	116.56%	77.01%	-50.03%	33.87%
Shares Outstanding (Basic)	322	322	323	323	323	322
Shares Outstanding (Diluted)	322	322	323	323	323	322
Shares Change (YoY)	-0.27%	-0.14%	0.09%	-0.21%	0.53%	-0.98%
EPS (Basic)	3.13	3.26	2.48	1.15	0.65	1.30
EPS (Diluted)	3.13	3.26	2.48	1.15	0.65	1.30
EPS Growth	24.64%	31.45%	116.37%	77.38%	-50.29%	35.19%
Free Cash Flow	827.53	957.19	1,042	735.41	-59.05	206.87
Free Cash Flow Per Share	2.57	2.97	3.23	2.28	-0.18	0.64
Dividend Per Share	1.957	1.957	1.492	0.574	0.260	0.392
Dividend Growth	31.21%	31.21%	159.93%	120.69%	-33.72%	-32.64%
Gross Margin	94.21%	94.23%	94.94%	91.98%	89.44%	85.75%
Operating Margin	29.49%	31.83%	33.14%	26.94%	26.78%	29.66%
Profit Margin	35.80%	37.46%	25.55%	14.48%	9.77%	30.45%
Free Cash Flow Margin	29.40%	34.10%	33.24%	28.79%	-2.76%	15.07%
EBITDA	905.79	967.64	1,107	757.52	654.2	484.95
EBITDA Margin	32.18%	34.48%	35.31%	29.65%	30.59%	35.32%
D&A For EBITDA	75.74	74.2	68.05	69.24	81.45	77.63
EBIT	830.05	893.44	1,039	688.27	572.75	407.32
EBIT Margin	29.49%	31.83%	33.14%	26.94%	26.78%	29.66%
Effective Tax Rate	8.52%	8.25%	9.79%	19.01%	16.41%	10.56%
Revenue as Reported	7.89	-	-	2,555	2,139	1,373
Advertising Expenses	-	6.23	2.22	0.05	0.24	0.42

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.